BCL9L and urinary bladder carcinoma: For instance, BCL9L, as a co-activator of β-catenin, shows that its upregulated expression can markedly enhance the activity of the Wnt/β-catenin pathway in bladder cancer cells, thereby promoting their proliferation, migration, and invasion.